{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:42Z","timestamp":1791105702316,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dr. Karolina Jus"},{"name":"Atuka Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.pnpbp.2012.12.008","type":"journal-article","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T21:00:18Z","timestamp":1357678818000},"page":"151-156","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques"],"prefix":"10.1016","volume":"43","author":[{"given":"James B.","family":"Koprich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Jarvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Seeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pnpbp.2012.12.008_bb0005","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.pnpbp.2012.12.008_bb0010","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"Blanchet","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pnpbp.2012.12.008_bb0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00726-006-0320-3","article-title":"Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease","volume":"32","author":"Bonsi","year":"2007","journal-title":"Amino Acids"},{"issue":"8","key":"10.1016\/j.pnpbp.2012.12.008_bb0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.20612","article-title":"Nondopaminergic mechanisms in levodopa-induced dyskinesia","volume":"20","author":"Brotchie","year":"2005","journal-title":"Mov Disord"},{"issue":"18","key":"10.1016\/j.pnpbp.2012.12.008_bb0025","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1097\/00001756-199412000-00045","article-title":"NMDA receptor blockade reverses motor response alterations induced by levodopa","volume":"5","author":"Engber","year":"1994","journal-title":"Neuroreport"},{"issue":"71","key":"10.1016\/j.pnpbp.2012.12.008_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-211-33328-0_1","article-title":"Levodopa in the treatment of Parkinson's disease","author":"Fahn","year":"2006","journal-title":"J Neural Transm Suppl"},{"issue":"4","key":"10.1016\/j.pnpbp.2012.12.008_bb0045","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.1148","article-title":"Neural mechanisms underlying peak\u2013dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan","volume":"16","author":"Fox","year":"2001","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.pnpbp.2012.12.008_bb0050","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","article-title":"Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure","volume":"21","author":"Fox","year":"2006","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.pnpbp.2012.12.008_bb0060","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","article-title":"Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease","volume":"63","author":"Fox","year":"2006","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.pnpbp.2012.12.008_bb0035","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","article-title":"Non-dopaminergic treatments in development for Parkinson's disease","volume":"7","author":"Fox","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pnpbp.2012.12.008_bb0040","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0079-6123(08)00923-0","article-title":"Parkinson's disease\u2014opportunities for novel therapeutics to reduce the problems of levodopa therapy","volume":"172","author":"Fox","year":"2008","journal-title":"Prog Brain Res"},{"issue":"1","key":"10.1016\/j.pnpbp.2012.12.008_bb0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","article-title":"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease","volume":"37","author":"Fox","year":"2010","journal-title":"Can J Neurol Sci"},{"issue":"5","key":"10.1016\/j.pnpbp.2012.12.008_bb0070","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","article-title":"Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004","volume":"20","author":"Goetz","year":"2005","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.pnpbp.2012.12.008_bb0065","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.pnpbp.2012.12.008_bb0075","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ana.22423","article-title":"Therapies for dopaminergic-induced dyskinesias in Parkinson disease","volume":"69","author":"Gottwald","year":"2011","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.pnpbp.2012.12.008_bb0080","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2004.11.008","article-title":"Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"48","author":"Hallett","year":"2005","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pnpbp.2012.12.008_bb0085","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.pnpbp.2012.12.008_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00702-009-0323-9","article-title":"The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa","volume":"117","author":"Jackson","year":"2010","journal-title":"J Neural Transm"},{"issue":"3","key":"10.1016\/j.pnpbp.2012.12.008_bb0095","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2012.12.008_bb0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1192\/bjp.180.5.465-a","article-title":"Atypical antipsychotics, cortical D(2) receptors and sensitivity to endogenous dopamine","volume":"180","author":"Kapur","year":"2002","journal-title":"Br J Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2012.12.008_bb0105","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/mds.23631","article-title":"The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease","volume":"26","author":"Koprich","year":"2011","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.pnpbp.2012.12.008_bb0110","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s11940-011-0121-1","article-title":"Dementia in Parkinson's disease","volume":"13","author":"Kurtz","year":"2011","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"10.1016\/j.pnpbp.2012.12.008_bb0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1527-3458.2006.00149.x","article-title":"Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP","volume":"12","author":"Lea","year":"2006","journal-title":"CNS Drug Rev"},{"issue":"5","key":"10.1016\/j.pnpbp.2012.12.008_bb0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11632030-000000000-00000","article-title":"Off-label use of atypical antipsychotics: cause for concern?","volume":"26","author":"McKean","year":"2012","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.pnpbp.2012.12.008_bb0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1016\/j.pnpbp.2012.12.008_bb0130","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov Disord"},{"issue":"11","key":"10.1016\/j.pnpbp.2012.12.008_bb0135","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/mds.20988","article-title":"Development of dyskinesias in a 5-year trial of ropinirole and L-dopa","volume":"21","author":"Rascol","year":"2006","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.pnpbp.2012.12.008_bb0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2012.12.008_bb0145","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14728222.10.4.515","article-title":"Targeting the dopamine D2 receptor in schizophrenia","volume":"10","author":"Seeman","year":"2006","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.pnpbp.2012.12.008_bb0150","unstructured":"Seeman P. 2010 Publication date Jan. 7, 2010. Substituted butyrophenone derivatives. USA."},{"issue":"6","key":"10.1016\/j.pnpbp.2012.12.008_bb0155","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/ajp.156.6.876","article-title":"Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine","volume":"156","author":"Seeman","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2012.12.008_bb0160","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.expneurol.2010.09.007","article-title":"The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets","volume":"226","author":"Tayarani-Binazir","year":"2010","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.pnpbp.2012.12.008_bb0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnnp.2004.036558","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2012.12.008_bb0170","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.bmc.2011.02.033","article-title":"Molecular properties affecting fast dissociation from the D2 receptor","volume":"19","author":"Tresadern","year":"2011","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"10.1016\/j.pnpbp.2012.12.008_bb0175","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","article-title":"A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease","volume":"19","author":"van der Stelt","year":"2005","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.pnpbp.2012.12.008_bb0180","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.pnpbp.2012.12.008_bb0185","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.pnpbp.2012.12.008_bb0190","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11910-007-0046-y","article-title":"Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment","volume":"7","author":"Zesiewicz","year":"2007","journal-title":"Curr Neurol Neurosci Rep"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584612003193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584612003193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T16:30:42Z","timestamp":1745944242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584612003193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":38,"alternative-id":["S0278584612003193"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2012.12.008","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}